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Systematic reviews represent powerful tools to identify, collect, synthesize, and evalu-
ate primary research data on specific research questions in a highly standardized and 
reproducible manner. They enable the defensible synthesis of outcomes by increasing 
precision and minimizing bias whilst ensuring transparency of the methods used. This 
makes them especially valuable to inform evidence-based risk analysis and decision 
making in various topics and research disciplines. Although seen as a “gold standard” for 
synthesizing primary research data, systematic reviews are not without limitations as they 
are often cost, labor and time intensive and the utility of synthesis outcomes depends 
upon the availability of sufficient and robust primary research data. In this paper, we (1) 
consider the added value systematic reviews could provide when synthesizing primary 
research data on genetically modified organisms (GMO) and (2) critically assess the ade-
quacy and feasibility of systematic review for collating and analyzing data on potential 
impacts of GMOs in order to better inform specific steps within GMO risk assessment 
and risk management. The regulatory framework of the EU is used as an example, 
although the issues we discuss are likely to be more widely applicable.
Keywords: GMo, risk assessment, risk management, evidence synthesis, systematic review, bias
Introduction
In many countries, genetically modified organisms (GMO) and their food or feed products have to 
undergo a stringent and science-based risk assessment before being placed on the market. In general, 
the risk assessment process follows a multi-step approach to identify and characterize a possible 
hazard and to determine the likelihood of its occurrence in order to conclude about a possible risk 
posed by a certain GMO. For each step, targeted scientific information has to be provided by the 
applicant who is in charge of applying for the release of a GMO into the environment to (1) frame 
the risk assessment and facilitate the elaboration and clarification of testable hypotheses and (2) allow 
risk assessors to provide scientific opinions on the overall safety in order to inform risk management. 
In the EU, for example, risk management includes specific monitoring activities and foresees the 
possibility for the evocation of safeguard clauses and emergency measures if new scientific informa-
tion contesting a former risk conclusion becomes available (EC, 2001, 2003; EFSA, 2010a, 2011a). 
Data informing GMO risk assessment and risk management can take various forms and includes 
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primary research data generated by the applicant and secondary 
research outcomes summarizing the available evidence base 
(EFSA, 2010a). The scientific literature assessing possible impacts 
of GMOs on human and animal health and the environment is 
sometimes characterized by heterogeneous results and conclu-
sions (Devos et al., 2014b), compounded by the complexity and 
the diversity of test designs and the multitude of endpoints under 
investigation. In addition, the absence of tangible assessment 
criteria can hinder a clear and straightforward judgment about 
the validity and the relevance of the information for GMO risk 
assessment and risk management.
Systematic reviews are evidence synthesis approaches which 
have become well established in medical science to support evi-
dence-based decision making (Guyatt, 1992). Their use is expand-
ing to other disciplines to inform policy decisions, for example, in 
the areas of social welfare, international development, education, 
crime and justice1, environmental management2, and  –  more 
recently – food/feed safety assessment (EFSA, 2010b). Systematic 
reviews are based on a standardized and rigorous methodology 
to improve precision, minimize bias, and increase transparency, 
which are prerequisites for a robust synthesis of existing evidence. 
Thus, systematic reviews are especially valuable for synthesizing 
evidence relating to contentious topics for which stakeholders 
may hold differing views. Even though seen as a “gold standard” 
when summarizing primary data, systematic review methodol-
ogy has limitations, for example it can be demanding on resources 
such as time, money, and manpower, and may not be worthwhile 
if the availability and robustness of primary research data (i.e., 
original data generated by one or more research studies) are 
limited. Thus, the decision to perform a systematic review should 
always consider both the potential limitations and benefits.
In this paper, we consider the added value systematic reviews 
can provide when summarizing primary research data and we 
consider the possible adequacy and feasibility of systematic 
review for collating and analyzing data on potential impacts of 
GMOs in order to inform specific steps within GMO risk assess-
ment and risk management.
evidence synthesis and evidence-Based 
decision Making
Evidence synthesis refers to the process of gathering together 
information to answer a question. This can be done in a number 
of different ways, depending upon the type of question to be 
answered and whether the answer is intended to be illustrative 
and approximate (e.g., identifying general patterns or trends) or 
quantitatively reliable and precise (e.g., determining structural or 
input parameters for a quantitative model). A commonly used 
approach for answering scientific questions of both types is to 
conduct a literature review. Reviews of the literature vary con-
siderably in how they are conducted and if they do not follow an 
a priori defined and documented procedure that employs explicit 
means to identify, critically appraise, and evaluate included 
1 http://www.campbellcollaboration.org/
2 http://www.environmentalevidence.org
studies they are usually referred to as “traditional” or “narrative” 
reviews.
What is a systematic Review and  
Why Conduct one?
A systematic review is a structured, reproducible, and rigorous 
approach for answering a specific question (EFSA, 2010b). The 
key advantages of a systematic review over other types of evidence 
synthesis are that a systematic review can answer a question in a 
transparent manner that minimizes bias and maximizes preci-
sion. Bias is minimized by following a standardized procedure, 
comprising eight steps, as illustrated in Table 1.
The Importance of Bias
Bias is defined as a systematic deviation in study results from 
their true value, i.e., it means either an underestimation or 
overestimation of the true value. Bias should not be confused 
with statistical uncertainty as a result of random error, which 
tABLe 1 | Core steps in the conduct of a systematic review.
steps of the 
systematic review
Key procedures
1. Preparing the 
review
The review question is clearly specified and a protocol 
detailing the review methods is developed. The protocol 
should be subject to peer review and could include 
stakeholder involvement in its development or peer review
2. Searching for 
evidence
An extensive search is conducted based on a pre-
specified search strategy which aims to identify all 
relevant evidence, reducing the risk of selection bias
3. Selecting studies 
for inclusion or 
exclusion in the 
review
The identified evidence is assessed against eligibility 
criteria specified in the protocol to ensure that only 
appropriate evidence is included in the review, reducing 
risk of bias from selective evidence inclusion
4. Collecting data 
from the included 
studies and creating 
evidence tables
Data are collected from the included studies using a 
standard, pilot-tested form to ensure that only relevant 
data are extracted, in a way that minimizes errors
5. Assessing 
methodological rigor 
of included studies
The primary research studies are critically assessed for 
study rigor, in particular any methodological aspects that 
could lead to risk of bias (referred to as internal validity) or 
issues of generalizability (referred to as external validity)
6. Synthesizing 
data from 
included studies, 
possibly including 
meta-analysis
Pooling of quantitative outcomes across similar primary 
studies may be conducted to improve precision of the 
answer, subject to the studies meeting adequate pre-
specified standards of rigor
7. Presenting data 
and results
Presentation of results is transparent, including a clear 
specification of the reasons why studies were excluded 
from the review and clear specification of how the 
analysis was conducted, including how any studies at risk 
of bias were handled
8. Interpreting 
results and drawing 
conclusions
The interpretation of qualitative and/or quantitative 
results takes into account any limitations of the included 
primary studies as well as any limitations of the review 
process. Stakeholders could be involved, e.g., if the 
draft systematic review report is circulated among 
stakeholders for comment. Implications for research/
policy/practice are provided but reviews should ensure 
that these do not over-reach the review findings
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is present in all research studies. Random error reflects uncer-
tainty in the study result due to statistical limitations of the study 
design and, as the name implies, it reflects inaccuracy of estima-
tion that is distributed randomly around the true result. Often, 
random error can be reduced by increasing the sample size in 
a research study, or by quantitatively combining the results of 
similar studies in a meta-analysis (subject to the studies being 
adequately comparable), hence improving the precision of the 
result (Glass, 1976). Bias, on the other hand, refers to a system-
atic error which cannot be reduced by increasing the sample size 
or pooling study results in a meta-analysis. If bias is present in 
primary research studies, their results are likely to be incorrect. 
Traditional non-systematic reviews of evidence which do not 
formally assess the rigor of primary research studies would not 
be able to detect this.
Bias in research studies can arise for a variety of reasons. 
Poor design of a research study may mean that it consistently 
underestimates or overestimates the true value of an outcome and 
the study researchers may not be aware of this. In some cases, 
researchers may have a vested interest in a particular outcome and 
this could lead, either intentionally or unintentionally, to various 
types of bias. Considerable experience from evidence synthesis 
in health research has shown that where bias is present it often 
leads to overestimation of beneficial outcomes, e.g., exaggerating 
the actual benefits of an intervention such as a drug treatment 
(Higgins and Green, 2011).
A number of tools are available for assessing the risk of bias 
in primary research studies but these depend on the study design 
and are mainly developed for randomized studies, e.g., in health 
research (Higgins and Green, 2011), and in research involving 
laboratory animals (Hooijmans et al., 2014). Even if a specific tool 
is not available to guide a risk of bias assessment for study designs 
relevant to a particular question, likely sources of bias have to be 
considered and a critical appraisal strategy has to be pre-specified 
in the review protocol.
In a traditional narrative review, bias could arise either from 
the primary studies included in the review or from the evidence 
synthesis process itself, for example if reviewers are selective in 
the evidence that they include or in the analysis methods they 
use. This latter bias in the review process itself is mitigated in 
systematic reviews through transparent and objective conduct 
and reporting of the processes undertaken.
Principles of Critical Appraisal in Evidence Synthesis
The critical appraisal of primary research studies is often referred 
to as “quality assessment” but the term “quality” is rather vague, 
without a consistent meaning, and has been interpreted by some 
as being possibly offensive to study investigators (Higgins and 
Green, 2011). When conducting a critical appraisal of primary 
research, it is important that the assessment focuses on aspects 
of methodological rigor that will have a direct bearing on inter-
preting the results of the evidence synthesis. There are two such 
aspects that need to be considered. These are the risk of bias and 
the generalizability of the findings. Studies which are conducted 
in such a way that they are considered to be at low risk of bias 
are said to have high “internal validity” and studies whose results 
are directly generalizable to answer the review question are said 
to have high “external validity.” These two aspects of critical 
appraisal are fundamentally important but differ in the way they 
are handled. Whilst the internal validity of a study (i.e., the extent 
to which it is likely to suffer from bias) is a property of the primary 
study in question, the external validity of a study is not a property 
of the study itself but is related to the question being answered 
(e.g., results of a well-conducted study on a GM crop might be 
generalizable to some countries but not others  –  so external 
validity of the findings would depend on which country a risk 
assessment question refers to).
Detailed consideration of critical appraisal and tools to aid in 
undertaking critical appraisal assessments in systematic reviews 
have been published in the medical science literature and, more 
recently, in environmental sciences. These considerations cover 
different types of biases, study designs, and the appropriateness 
of assessment tools (e.g., medical research: Katrak et  al., 2004; 
meta-analyses in agronomy: Philibert et al., 2012; environmental 
research: Bilotta et al., 2014).
What Makes Systematic Reviews Different?
Systematic reviews achieve the objectives of minimizing bias, 
maximizing precision, and ensuring transparency and reproduc-
ibility in a number of ways. Systematic reviews are best suited to 
answer specific questions. In general, if a primary research study 
can be envisaged that could answer a question, then it is likely 
that the same question can be addressed by a systematic review. 
A useful concept for considering whether a question would be 
answerable by a systematic review is to analyze the question 
structure in terms of “key elements” (EFSA, 2010b; Aiassa et al., 
2015). In questions about interventions, the key elements are the 
population(s) (P), intervention(s) (I), comparator(s) (C), and 
outcome(s) (O), all of which must be specified for the question 
to be answerable by a systematic review. A systematic review is 
based on a pre-specified protocol which ensures that the overall 
evidence synthesis is objective and should not be influenced 
by selective use of evidence or methods that could introduce 
errors or bias. The protocol should, ideally, be peer reviewed and 
updated if necessary before a review starts (step 1, see Table 1). 
The protocol should specify how each of the steps of the review 
will be conducted and by whom. Searching (step 2) aims to iden-
tify all relevant evidence using a pilot-tested search strategy and 
a range of evidence sources, including gray as well as academic 
literature. This is to reduce the risk of publication bias (i.e., the 
selective identification of the evidence due to positive or nega-
tive results being published preferentially over no-effect results 
in more accessible literature sources). The process for including 
relevant evidence into a systematic review (step 3) is based on 
clear selection criteria specified a priori in the protocol to ensure 
that the selection process is as objective and impartial as pos-
sible. Collection of data from the included studies (step 4) is also 
based on pre-specified criteria to ensure that the data collected 
directly inform the analysis. Data extraction forms are usually 
included in a systematic review report (e.g., in an appendix) so 
that the relationship between the data which are collected and 
those which are analyzed is transparent, minimizing the risk of 
unplanned selection of data subsets for preferential analysis. A 
systematic review always includes a critical appraisal step where 
tABLe 2 | Comparison of key aspects of traditional reviews and systematic reviews.
traditional “narrative” 
reviews
systematic reviews Reasons why systematic reviews may be advantageous for synthesizing 
evidence compared to non-systematic traditional (narrative) reviews
Review question Often broad in scope Focused and explicit The question is focused and a systematic review directly answers it, based on 
evidence identified explicitly as being the most relevant and robust
Criteria for inclusion or 
exclusion of studies
Not always explicitly 
stated
Pre-defined and 
documented; applied in a 
verifiable manner
The scope of the evidence is explicitly clear, meaning that evidence cannot 
be gathered selectively (systematic reviews reduce bias), irrelevant evidence 
is avoided (systematic reviews ensure efficiency), criteria are pre-defined 
(systematic reviews enable stakeholder involvement), and the criteria and 
process aim to be objective (systematic reviews reduce ambiguity or subjectivity 
of interpretation)
Review method Seldom reported Reported and also pre-
defined in a protocol
By explicitly and transparently reporting how and why evidence is collected, the 
synthesis can be clearly defensible, reproducible, and may be readily updated. 
Being a systematic and standard approach, the robustness of systematic 
reviews can be easily checked
Literature search Not always extensive Structured to identify as 
many relevant studies as 
possible
All relevant evidence is considered (systematic reviews identify and/or minimize 
publication bias) or, in cases where evidence is not included (e.g., confidential 
data) this can be made explicit so as to fully inform interpretation
Methodological critical 
appraisal of included 
studies
Variable Included, typically using a 
critical appraisal tool
Critical appraisal of the included evidence can ensure that systematic review 
findings reflect the truth in terms of their magnitude and direction (i.e., bias 
is minimized) with an appropriate degree of certainty – i.e., the estimates of 
outcomes and their precision levels are both valid. This is an important ‘filter’ 
in evidence synthesis that enables less rigorous evidence to be identified and 
handled appropriately
Critical appraisal 
example: reporting of 
study outcomes
Selective reporting; 
often of study author’s 
interpretation
Full reporting of relevant 
outcomes (numerical results)
By exposing and/or controlling for selective reporting, systematic reviews can 
minimize reporting bias which could be a problem in cases where stakeholders 
have vested interests in certain outcomes
Synthesis Usually narrative, 
sometimes selective
Quantitative synthesis (meta-
analysis) when possible
Where possible, systematic reviews make use of the best available evidence 
to improve precision of the answer; explicit exploration of assumptions and 
limitations is possible, e.g., in sensitivity analyses
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the methodological rigor and generalizability of the included 
primary studies is evaluated (step 5). Whilst internal validity 
should always be assessed in a systematic review, the assessment 
of external validity may or may not be necessary depending upon 
the nature of the review question and the primary studies that 
may answer it. Studies which are considered to be at high risk of 
bias may then be either excluded from the data synthesis (step 
6) or included in sensitivity analyses to clarify their impact on 
the review’s conclusions. A systematic review may or may not 
support a quantitative pooling of outcomes across studies, i.e., 
a meta-analysis. This depends, among other factors, on whether 
the studies are methodologically and statistically homogeneous. 
The reasons for conducting or not conducting a meta-analysis 
should be transparently stated and consistent with the planned 
approach specified in the review protocol. The presentation of 
data and results (step 7) should follow a clear and logical structure 
so that the roles of the primary studies informing the review’s 
results can be readily deduced and reasons for the exclusion from 
analysis of any studies which met the initial inclusion criteria are 
explained. The final part of a systematic review, where the results 
are interpreted and conclusions drawn (step 8), should demon-
strate that the conclusions are based directly on the results of the 
review, and should also include a critical reflection stating any 
limitations of the review itself and the implications they have for 
the review’s conclusions.
A comparison of systematic against traditional narrative 
reviews is shown in Table 2.
Systematic Reviews Facilitate Stakeholder 
Involvement
A systematic review has the potential to minimize bias by encour-
aging researchers to find and transparently document all relevant 
evidence. Stakeholders have an important role to play, e.g., in 
helping to determine which questions in a risk assessment have 
highest priority for a systematic review. They may also provide 
guidance to inform the review processes. Although in theory 
relevant stakeholders could contribute to any type of evidence 
synthesis, including traditional narrative reviews, the structured 
systematic approach of systematic reviews is particularly well-
suited for involving stakeholders. It is important to ensure that 
stakeholder participation is appropriately balanced rather than 
representing only certain viewpoints and neglecting others.
For a systematic review to function efficiently, it is generally 
not feasible to involve stakeholders in all the steps, particularly if 
the range of stakeholders is very broad. But there are key points 
in the review process where stakeholders could, and arguably 
should, be involved. These are in preparing the review (step 1) 
and interpreting the results and drawing conclusions (step 8). A 
relatively straightforward approach for involving stakeholders in 
preparing the review is to invite them to comment on or contrib-
ute to developing the review protocol. This could be done as part 
of the review planning and/or formal peer review of the protocol. 
A relatively straightforward approach for involving stakeholders 
at the point of interpreting the results and drawing conclusions 
could be to invite them to comment on a draft of the systematic 
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review report, and/or to be involved in the formal peer review of 
the final published version of the report. If stakeholders do con-
tribute to a systematic review, it is important that their roles and 
interests are clearly acknowledged (Saan et  al., 2015). Another 
option is to recruit stakeholders to an advisory group which can 
inform the review, but to avoid an unbalanced influence of spe-
cific stakeholders the role of the advisory group should be clearly 
specified in the review protocol and subsequently adhered to.
When involving stakeholders in an evidence synthesis, it 
is important that the stakeholders are clearly informed of the 
purpose of the evidence synthesis so that they can comment in 
an appropriate manner.
Limitations of systematic Reviews
Whilst systematic reviews offer valuable opportunities to reli-
ably synthesize evidence on specific topics, they are not without 
limitations. Systematic reviews should be based on a specific, 
well-defined review question that is established at the start of the 
review. This may prove to be a challenge, particularly where topics 
are dynamic and the precise area of stakeholder interest may be 
fluid, but it is vital to ensure that the review remains on target and 
the outputs are useful. Furthermore, as a systematic review by 
definition has a minimum number of steps which should be com-
pleted by a minimum number of people (usually a review team 
is recruited), it can be relatively resource intensive compared to 
a traditional narrative review and cannot provide an immediate 
answer to a question (since the development of the review proto-
col and then following the subsequent steps of the process usually 
take months rather than days or weeks). However, the relatively 
high resource requirement and lack of immediate results from 
a systematic review have to be weighed against the need for an 
answer that is valid and precise. As the validity and the precision 
of synthesis outcomes depend on the reliability and the quantity 
of included studies, performance of systematic reviews may only 
be useful to support regulatory decision-making processes when 
sufficient and robust primary data are available.
systematic Reviews Can Inform evidence-Based 
decision-Making Processes
An example where systematic reviews are employed routinely as a 
standard approach for evidence synthesis in support of regulatory 
decision making is the technology appraisal process used by the 
National Institute for Health and Care Excellence (NICE) for 
approving the use of health technologies (including drugs, other 
treatments, devices, and tests) in England and Wales (NICE, 
2013). The NICE appraisal process requires that applicants seek-
ing approval of a health technology should provide systematic 
review(s) of the clinical effectiveness of the technology. The 
process is highly structured and involves stakeholders (including 
independent academic groups, companies and sponsors, health-
care professionals, commissioners of health services, and patient 
or carer representatives) at several steps, including the initial 
definition of the scope of the technology appraisal. The evidence 
submitted by an applicant, including its systematic review(s), is 
critically assessed by an independent academic assessment group 
which reports to NICE, and further information or analyses 
may be requested by NICE from the applicant if necessary. A 
final decision on the approval of the technology is made at one 
or more appraisal committee meetings which include NICE, 
the applicant, the independent assessment group, and other 
stakeholders. The appraisal process and the rationale for the final 
decision are reported transparently on the NICE website for each 
technology that is assessed3. The use of systematic reviews in the 
NICE decision-making process is well established: between 1st 
March 2000 and 31st March 2015, NICE conducted 553 technol-
ogy appraisals which yielded 578 individual recommendations4. 
Even though the approval process followed by NICE differs in 
some ways from the regulatory approval process of GMOs, it 
illustrates the value that systematic reviews can have in support-
ing regulatory decision making.
GMo Risk Assessment and Risk 
Management Require the Provision of 
targeted scientific Information
While regulation of GMOs differs between jurisdictions, the 
decision-making process is always based on science-based risk 
assessment. The underlying frameworks aim to identify, charac-
terize, and evaluate the likelihood that an adverse effect might 
occur and to determine the need for the implementation of risk 
management measures (EPA, 1998; EC, 2001, 2003; Environment 
Canada, 2012).
Environmental risk assessment of GMOs in the EU follows 
the EFSA guidance for genetically modified plants (EFSA, 2010a) 
and generally comprises six major steps, including (1) problem 
formulation and hazard identification, (2) hazard characteriza-
tion, (3) exposure characterization, (4) overall risk characteriza-
tion by placing the magnitude of consequences in relation to 
the probability of their occurrence, (5) the development of risk 
management strategies, and (6) an overall risk evaluation (EFSA, 
2010a). Risk assessment of GMOs for food or feed safety evalua-
tion follows a similar approach (EFSA, 2011a). The core of each 
risk assessment is built up by a comparative safety assessment 
which considers the characteristics of the GMO and its closest 
non-GM counterpart in order to identify possible hazards that 
further determine the scope of the risk assessment (Kok and 
Kuiper, 2003). Furthermore, EU regulation demands, as part 
of the risk management, the development of a post-market 
environmental monitoring plan in order to “identify any direct 
or indirect, immediate and/or delayed adverse effects of GMOs, 
their products and their management to human health or the 
environment, after the GMO has been placed on the market” 
(EFSA, 2010a). In addition, EU regulation foresees the possibility 
for the evocation of safeguard clauses and emergency measures 
if new scientific information contesting former risk assessment 
conclusions becomes available (EC, 2001, 2003).
In order to draw conclusions about possible risks, targeted 
scientific information is considered for the different risk assess-
ment/risk management steps, so that each step supplies sufficient 
evidence in order to quantify and describe each risk identified. 
3 https://www.nice.org.uk/guidance/published?type=ta
4 https://www.nice.org.uk/news/nice-statistics
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The evidence base to satisfy the respective data requirements may 
derive from a variety of sources, such as primary and secondary 
research studies or, in cases lacking primary evidence, further 
research, e.g., data generated by the applicant. In line with the 
principle of the comparative safety assessment, the most fre-
quent questions likely to arise in GMO risk assessment and risk 
management would have a PICO structure. In such cases, the 
population is representing the entity under investigation (e.g., 
organisms exposed to the GMO), the intervention is usually the 
GM plant, trait, or event that the population is exposed to, the 
comparator is normally the closely related (e.g., near-isogenic) 
non-GM organism providing the baseline characteristics the 
intervention should be compared to, and the outcome is specify-
ing the assessment/measurement endpoints being considered. 
Questions about occurrence or consumption, or about the 
accuracy of test methods, may also be relevant for a complete 
impact assessment, and these have different key elements (i.e., 
other than PICO structure) which would need to be specified [for 
more detail see EFSA (2010b), Aiassa et al. (2015)].
Thus, the systematic review methodology might offer a stand-
ardized approach to provide robust data compatible with the 
demands of GMO risk assessment and risk management. To be 
clear, systematic reviews might be considered as a robust means 
of collating the evidence which is used to inform the different 
stages of the assessment process but should not be seen as an 
integral part of GMO risk assessment or risk management. In 
the following sections, we discuss how systematic reviews could 
provide rigorous syntheses of GMO data, such as comparative 
impact data, and consider the benefits, challenges, and limitations 
of performing systematic reviews for this purpose (see Table 3).
Are systematic Reviews Appropriate tools to 
Inform specific GMo Risk Assessment/Risk 
Management steps?
To help in weighing up the appropriateness of systematic reviews 
to inform GMO risk assessment and risk management, potential 
benefits, challenges, and limitations relevant for each step are 
briefly summarized here.
Potential benefits to risk assessment and risk management of 
systematic reviews are as follows:
- Increasing precision by means of a quantitative data synthesis, 
e.g., via meta-analysis, thereby facilitating the clarification of 
uncertainties.
- Minimizing bias by the elaboration of a review protocol and by 
the impartial application of assessment criteria.
- Increasing transparency by assuring thorough documentation 
of the review process.
- Facilitating stakeholder involvement (e.g., by discussion of the 
review protocol).
- Facilitating updating by following a standardized and thor-
oughly recorded procedure.
- Facilitating a transparent communication of assessment details 
by means of the review report might increase the traceability of 
review conclusions for risk assessors and risk managers (e.g., 
why were certain studies included in the review and others not, 
which criteria were applied during critical appraisal, and how 
were the appraisal results considered during the synthesis step?).
Potential challenges and limitations of systematic reviews are 
as follows:
- Systematic reviews can be resource intensive and are thus not 
always feasible.
- Systematic reviews do not provide an immediate answer to a 
question.
- Where answers are required for many questions, prioritization 
of questions may be appropriate. One prioritization approach 
suggested by Aiassa et al. (2015) would consider how influen-
tial the answer to the question will be for the overall risk assess-
ment, with those questions (or model parameters) which have 
the greatest influence being prioritized for evidence synthesis.
- Sufficient primary research data would have to be available for 
a systematic review to usefully inform risk assessment or risk 
management; this may not be likely for novel or rarely studied 
traits or events (it is more likely that there would be sufficient 
evidence for stacked events, where the respective single events 
have already been studied in detail, or for renewals of approval 
applications).
Due to these possible limitations, the appropriateness of 
systematic reviews might strongly depend on the specific topic 
and question under assessment and a decision for or against their 
performance would have to be made on a case-by-case basis. 
Possible points where systematic reviews could inform the spe-
cific risk assessment and risk management steps are considered 
in the following sections, and are illustrated, with their potential 
strengths and limitations, in Table 3.
Can Systematic Reviews Inform GMO Risk 
Assessment?
Each risk assessment begins with the identification and formula-
tion of a problem in order to identify the areas of greatest uncer-
tainty or concern to be considered during risk characterization 
(EPA, 1998; Hill and Sendashonga, 2003; EFSA, 2010a; Devos 
et al., 2012).
Central steps at the problem formulation stage are the defini-
tion of assessment endpoints, which are explicit and unambiguous 
targets for protection extracted from legislation and public policy 
goals, and the identification of possible hazard(s) and exposure 
route(s) through which the GM plant may adversely affect or inter-
act with the environment (EPA, 2003; Sanvido et al., 2012). These 
enable testable hypotheses to be derived to support a quantitative 
evaluation during hazard and exposure characterization (EFSA, 
2010a). Depending on the scope of the different risk assessment 
models, relevant information facilitating their development and the 
elaboration of a final risk analysis plan could be crop, trait, or event 
specific and may stem from various sources, including scientific lit-
erature, topic expert opinions, and new research data e.g., generated 
in the context of applications (i.e., unpublished scientific studies).
Systematic reviews could contribute to problem formula-
tion (Table  3). Expert knowledge informs the development 
of the problem formulation and hence the identification of 
tABLe 3 | systematic reviews and their adequacy to inform GMo risk assessment and risk management.
steps in GMo risk assessment and 
risk management according to eFsA 
(eFsA, 2010a) and directive 2001/18/
eC (eC, 2001)
data typically 
informing each step
Added value of sR methodology Challenges/limitations for sR performance
GMo RIsK AssessMeNt
Problem formulation/hazard 
identification (devos et al., 2012)
•  Identification of characteristics of 
the GMO that might cause potential 
adverse effects
• Identification of exposure pathways
• Definition of assessment endpoints
•  Formulation of testable hypotheses to 
frame subsequent RA steps
• Elaboration of analysis plans
Crop/trait/event and 
related management 
systems
Sources
(1) Published scientific 
literature
(2) Unpublished scientific 
studies
(3) Topic expert opinions
Potential added value when synthesizing primary research outcomes from sources  
1 and 2
• Increase precision
• Minimize bias
• Ensure transparency
• Facilitate stakeholder involvement
• Clarify uncertainty
Resulting benefits
•  SR could support a rigorous evaluation of relevant parameters, e.g., assessment endpoints 
and exposure pathways (if sufficient literature reporting relevant parameters exists, the 
reliability of the parameter estimates could be assessed and precision of the final estimate 
employed in the RA, improved by quantitative pooling where appropriate)
•  SR could provide defensible answers to support decisions when framing the scope of 
subsequent RA steps
•  SR could support targeted communication between assessors (and other stakeholders), by 
providing information in a standardized, well-structured way
SR and topic expert opinions (source 3): 
•  SR do not generally synthesize expert opinions; however, expert opinions are often valuable 
in setting the review question and developing the protocol and might contribute to decisions 
regarding the prioritization of different review questions
•  Sufficient primary research data would have to 
be available for a SR to be worthwhile and add 
value, which is not likely for novel traits/events 
or rarely used events
•  Could be time/labor/cost intensive depending 
upon the size of the evidence base
•  Question prioritization (based on problem 
formulation and/or conceptual models) might 
be needed
hazard/exposure characterization 
(eFsA, 2010a, 2011a)
•  Qualitative and/or quantitative 
evaluation of potential adverse effects
•  Quantitative estimation of the 
likelihood of exposure
Event/trait and related 
management systems
Sources
(1) Published scientific 
literature
(2) Unpublished scientific 
studies
Potential added value when synthesizing primary research outcomes from sources  
1 and 2
• Increase precision
• Minimize bias
• Ensure transparency
• Facilitate stakeholder involvement
• Clarify uncertainty
Resulting benefits
•  SR (including meta-analysis) could provide valid quantitative estimates with known precision 
regarding the intensity or likelihood of a hazard
•  SR could support a targeted communication between assessors (and other stakeholders), by 
providing information in a standardized, well-structured way
•  Sufficient primary research data would have to 
be available for a SR to be worthwhile and add 
value, which is not likely for novel traits/events 
or rarely used events
•  Could be time/labor/cost intensive depending 
upon the size of the evidence base
• Question prioritization might be needed
Risk characterization (eFsA, 2010a, 
2011a)
•  Qualitative and/or (semi-) quantitative 
estimation, including attendant 
uncertainties of the probability of 
occurrence and severity of known or 
potential adverse effects
Event/trait and related 
management systems
Sources
Information gathered 
during hazard/exposure 
characterization
•  SR would be unlikely to add value here, since this step determines and quantifies risks based 
on data collected, analyzed, and interpreted at the previous steps
• Not applicable
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steps in GMo risk assessment and 
risk management according to eFsA 
(eFsA, 2010a) and directive 2001/18/
eC (eC, 2001)
data typically 
informing each step
Added value of sR methodology Challenges/limitations for sR performance
development of risk management 
strategies (eFsA, 2010a)
•  Reduce the identified risks to a level 
of no concern and consider defined 
areas of uncertainty
•  When possible the reduction of risk 
should be quantified
•  The reliability and efficiency of risk 
management characteristics should 
be assessed
Crop/trait/event and 
related management 
systems
Sources
(1) Published scientific 
literature
(2) Unpublished scientific 
studies
Potential added value when synthesizing primary research outcomes from sources 1 and 2
• Increase precision
• Minimize bias
• Ensure transparency
• Facilitate stakeholder involvement
• Clarify uncertainty
Resulting benefits
•  SR may support a rigorous evaluation of risk management measures and strategies
•  SR could support a targeted communication on assessment details between assessors (and 
other stakeholders), by providing information in a standardized, well-structured way
•  Could be time/labor/cost intensive depending 
upon the size of the evidence base
•  Primary data have to be available and 
accessible
• Question prioritization might be needed
overall risk evaluation and 
conclusions (eFsA, 2010a)
• Evaluation of the overall risk
Event and related 
management systems
Sources
Information gathered 
during previous RA steps
•  SR would be unlikely to add value here, since this step draws conclusions about an overall 
risk posed by a GMO, based on data collected, analyzed, and interpreted at the previous 
steps
• Not applicable
GMo RIsK MANAGeMeNt
Monitoring/general surveillance 
(devos et al., 2012)
•  Case-specific monitoring: Targeted 
investigations to reduce uncertainties 
identified in previous steps
•  General surveillance: tracking system 
states after market release of a 
GMO to anticipate cumulative and 
unintended effects
Trait/event and related 
management systems
Sources
(1) Scientific literature
(2) Unpublished scientific 
studies
(3) Farm questionnaires
(4) Existing monitoring 
networks
Potential added value when synthesizing primary research outcomes from sources  
1, 2, and 3
• Increase precision
• Minimize bias
• Ensure transparency
• Facilitate stakeholder involvement
• Ensure updatability
• Clarify uncertainty
Resulting benefits
•  SR (including meta-analysis) could provide valid quantitative (or qualitative) estimates of 
relevant outcomes with known precision
•  A SR could facilitate integration and weighing of new studies by providing a consistent and 
transparent evaluation scheme that is readily updatable
•  Updating an existing SR might be time/
labor/cost intensive if a large amount of new 
information has to be included
•  If a SR addressing a specific question does not 
already exist conducting a full new SR could be 
time/labor/cost intensive
•  Primary data have to be available and 
accessible
• Question prioritization might be needed
SR and existing monitoring networks (source 4)
•  The external applicability of information 
from existing monitoring networks might be 
questionable; if so this would have limited value 
for GMO RA
safeguard clause/“emergency 
measures”
•  Determine the need for RA update 
based on new available evidence
Event
Sources
(1) Scientific literature
(2) Unpublished scientific 
studies
Potential added value when synthesizing primary research outcomes from sources 1 and 2
• Increase precision
• Minimize bias
• Ensure transparency
• Ensure updatability
• Clarify uncertainty
Resulting benefits if new data are within the scope of an existing SR relevant to the RA
•  Weighing of the information and assessment of its impact on previous risk/safety conclusions 
(e.g., via sensitivity analysis)
•  Communication about possible shortcomings affecting the reliability of the new information, 
facilitated by SR since relevant information is provided in a structured, standardized way, 
including objective critical appraisal
•  Depending on the amount of new information, a 
timely answer might not be possible
•  Primary data have to be available and 
accessible
This table illustrates the different risk assessment (RA) and risk management (RM) steps which use scientific research data in order to conclude about the safety of a genetically modified organism (GMO). It identifies the nature of the 
considered data, the possible added value provided by systematic reviews (SR), and depicts the challenges and limits for their conduct.
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potential review questions and the elaboration of review pro-
tocols. However, various different questions being supported 
by a different amount of available evidence could arise during 
problem formulation and it would not be feasible (and may not 
be considered necessary) to answer all of these with systematic 
reviews. This implies that a prioritization process could be helpful 
to clarify where robust synthesis of the evidence could be most 
important and worthwhile. Problem formulation is typically 
supported by a conceptual model which sets out the protection 
goals, assessment endpoints, and measurement endpoints of the 
risk assessment and risk management (Wolt et  al., 2010; Gray, 
2012). The conceptual model could provide a logical structure 
for identifying which key variables and pathways (e.g., stressors, 
receptors, and exposure routes) systematic review might be 
applied in order to answer questions about them generated in the 
problem formulation.
Based on problem formulation outcomes, systematic reviews 
might be applied to synthesize evidence to be considered during 
hazard and exposure characterization and during the develop-
ment of risk management strategies (see Table 3). In both cases, 
the considered evidence may stem from the published scientific 
literature and/or from unpublished scientific studies.
During hazard and exposure characterization, potential 
adverse effects (hazards) are characterized by providing (1) 
a quantitative and/or qualitative estimate of the nature of the 
associated harm and (2) a quantitative estimation of the exposure 
and frequency or likelihood of the hazard (EFSA, 2010a). For 
example, trait- and event-specific information could be provided 
by a systematic review assessing impacts of Bt-maize cultivation 
on the abundance or ecological function of non-target organisms 
(Meissle et al., 2014).
In the course of the development of risk management strategies, 
questions about whether a characterized risk can be sufficiently 
managed to meet acceptable levels of concern, and about the reli-
ability and efficiency of the proposed risk management strategies 
will be addressed (EFSA, 2010a). Here, systematic reviews could 
provide robust statements about factors which can influence the 
efficiency of management strategies. For example, the information 
provided by a systematic review can inform the baseline suscepti-
bility assessment of different lepidopteran and coleopteran maize 
pests to Bt-proteins (Gathmann and Priesnitz, 2014).
Can Systematic Reviews Inform GMO Risk 
Management?
Monitoring and general surveillance
After approval for the commercial release (cultivation and/or 
import and processing) of a GMO in the EU, it is mandatory that 
it is monitored for the occurrence of adverse effects (EC, 2001; 
EFSA, 2010a, 2011a).
Monitoring plans should consider case-specific monitoring 
aimed at assessing risks and/or uncertainties identified during the 
risk assessment process. In addition, post-market environmental 
monitoring also includes a requirement for general surveillance 
to be performed to assess any unanticipated effects arising from 
the use of the GMO.
Data informing the general surveillance can stem from 
a multitude of different sources in heterogeneous formats 
(Graef et  al., 2008; Wilhelm et  al., 2009; Smit et  al., 2012). 
Information sources may include scientific literature, data gener-
ated by the applicant through farm questionnaires, or data from 
existing monitoring networks (EFSA, 2011b). Once a consider-
able evidence base is available, the updatability of systematic 
reviews could allow the integration and weighing of new studies 
by following established protocols. This would further support a 
targeted discussion about (new) evidence arising from monitor-
ing data and inform risk assessors, managers, or other stakehold-
ers of any changes in review outcomes caused by their inclusion.
In general surveillance, there is an obligation for applicants 
to review existing data relating to their event. This will therefore 
require reviewing event as well as related trait data. At present, 
there is a recommendation to follow the systematic literature 
review methodology to select relevant evidence (EFSA, 2011b) 
in order to increase the defensibility of the information provided. 
The scope of the general surveillance, namely the detection of any 
unintended effect that was not anticipated in the risk assessment, 
would be much too broad for a single systematic review. Thus, 
specific questions would need to be identified, prioritized, and 
(depending on the availability of resources) subjected to one or 
more systematic review(s).
As mentioned above, further information to be considered 
during general surveillance may stem from farm questionnaires 
and existing monitoring networks (or monitoring reports). Farm 
questionnaires frequently provide categorized qualitative data 
(Berensmeier et  al., 2006) and thus a systematic review might 
in principle be applied to assess the impact of GM crop culti-
vation on enquired variables over time at different integration 
levels (trait or event). The integration of information provided by 
existing monitoring networks for general surveillance is largely 
hindered by a poor comparability between the data formats (e.g., 
inconsistencies in recording and sampling methods) (EFSA, 
2011b; Smets et al., 2014). By providing a standardized approach 
for assimilating evidence, systematic reviews might contribute to 
improved harmonization of the data collection.
In case-specific monitoring, applicants are asked to discuss 
the results of the monitoring in relation to current knowledge 
in order to clarify uncertainties identified during the risk assess-
ment (EFSA, 2010a, 2011b). This could be done by a systematic 
review by providing a robust summary of the available evidence 
base for a specific question.
Safeguard clauses and emergency measures
Once a GMO is approved, Directive 2001/18/EC and Regulation 
(EC) 1829/2003 allow member states to invoke safeguard clauses or 
further emergency measures to restrict or prohibit the marketing 
of the GMO on their territory if new information relevant to the 
safety of the GMO becomes available. Once the EC is notified by 
a Member State about such a request, EFSA receives the mandate 
to evaluate the scientific justification for such an invocation based 
on the information submitted by the Member State (EC, 2002; 
Devos et al., 2014a). The possibility to invoke such measures is not 
likely to be affected by the recent opt-out provision, allowing EU 
member states to restrict or ban the cultivation of GM crops on 
their own territory without following a science-based reasoning 
(EC, 2015).
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Data supporting the invocation of safeguard clauses and emer-
gency measures may be derived from scientific literature or any 
sources that provide relevant primary research findings. In order 
to decide and to communicate explicitly if the new information 
overturns former risk assessment conclusions and risk manage-
ment decisions, a systematic review would be a tool of choice to 
scientifically determine whether the addition of the new informa-
tion changes the outcome of a systematic review, provided that 
the new data are within the scope of an existing systematic review 
already used to inform GMO risk assessment and are available 
in the public domain. In this case, a systematic review might be 
updated to determine the weight and impact of the new informa-
tion on the overall conclusions e.g., via sensitivity analysis.
However, updating and reanalyzing a systematic review may be 
too time consuming, hindering the provision of a timely answer 
which may be required if there are concerns about imminent 
harm. In such a case, the critical appraisal criteria made explicit 
in the protocol could be directly applied to assess the robustness 
of the new information but a statement regarding their possible 
impact on former review conclusions could only be given once 
updating is finalized.
discussion
By increasing precision and transparency, minimizing bias, 
facilitating stakeholder involvement, and clarifying uncertainty, 
systematic reviews can provide robust quantitative and/or quali-
tative answers to specific scientific questions and are frequently 
applied e.g., in medical sciences to support decision-making 
processes (see Systematic Reviews Can Inform Evidence-Based 
Decision-Making Processes). Besides an increase in the robust-
ness of evidence synthesis outcomes, an additional advantage of 
systematic review methodology might stem from a structured and 
transparent presentation of assessment details by means of the 
review protocol. Thus, the scientific basis for any decision to be 
made during the synthesis process is made explicit a priori, thereby 
increasing the traceability of review conclusions for risk assessors 
and risk managers. Systematic review performance is not free from 
challenges and limitations as it may be highly time, labor, and cost 
intensive. In addition, sufficient primary data have to be available 
for a systematic review to be worthwhile. Thus, when adopting 
systematic review methodologies for the support of decision-
making processes, three fundamental questions would need to 
be considered. (1) Would one or more systematic reviews provide 
data compatible with the demands of the decision-making process? 
(2) Would the performance of these systematic reviews be feasible 
when considering the associated challenges and limitations? (3) 
Would the review(s) add value to the decision-making process 
compared to existing methods used for synthesizing the evidence?
Genetically modified organisms risk assessment and risk 
management require comparative quantitative and/or qualitative 
estimates of impacts in order to draw conclusions about the risks 
of a GMO. PICO-type questions already resemble the concept of 
the comparative assessment, supporting the appropriateness 
of systematic reviews to inform specific risk assessment or risk 
management steps about possible impacts of a GMO on the 
environment and on human and animal health. As most of the 
information to be provided in the approval process for GMOs is 
focused on a specific event, the availability of primary research 
data could be a major limitation restricting the use of systematic 
reviews. Thus, systematic reviews might only be feasible on 
a case-by-case basis where the available evidence base would 
justify their conduct. By contrast, in the EU the Implementing 
Regulation (EU) No 503/2013 (EC, 2013) on applications for 
authorization of genetically modified food and feed requests the 
applicant to “ include a systematic review [….] on potential effects 
on human and animal health of the genetically modified food and 
feed covered by the application”. In practice, this would not be 
feasible with a single systematic review, which requires a specific 
question to be specified, so the problem would need to be broken 
down into a set of more specific questions. Hence, the intended 
meaning of this statutory requirement needs clarification.
A considerable challenge for systematic reviews is the problem 
of publication bias. This refers to the tendency for scientific jour-
nals to publish papers that report significant or “novel” results, 
whereas studies that do not reveal significant effects may not even 
be submitted for publication. This has been well documented and 
investigated in the medical sciences (Parekh-Bhurke et al., 2011) 
and although likely also in the field of GMO risk assessment, so 
far no research has quantified the extent of publication bias in 
relation to GMO research. A central tenet of systematic review 
methods is that the possibility of publication bias should be mini-
mized by undertaking searches for gray literature, which includes 
‘file-drawer’ studies, such as theses and pre-prints, non-standard 
academic reports, such as meeting abstracts, and practitioner-
generated research, such as organizational reports and evaluations 
(Haddaway and Bayliss, 2015). Statistical methods are available to 
assess publication bias (Higgins and Green, 2011; Jin et al., 2015). 
However, a considerable number of studies in the field of GMO 
impact assessment have been conducted for regulatory purposes 
and have never been published. Such studies are typically included 
in applications for market releases and can in many jurisdictions 
only be accessed by regulatory bodies. Hence, their identification 
and inclusion in publicly accessible systematic reviews would face 
considerable hurdles. For example, in the EU, first relevant studies 
need to be identified by gaining read access to an application (from 
EFSA), and then permission for the further use of study data must 
be obtained from the data owner. Therefore, a considerable body 
of evidence would likely be excluded from evidence syntheses that 
require data from regulatory applications.
In principle, a systematic review could be a robust way to 
assess new scientific evidence since it can transparently describe 
the weight and impact of the new information on existing review 
outcomes and conclusions. However, if a timely answer is needed 
e.g., in the case of urgent policy questions, it may only be feasible 
to systematically assess the new information if it is within the 
scope of an existing systematic review. If no systematic review 
with the same scope is available, it is unclear what to do in such a 
situation, e.g., whether it may be acceptable to limit the searches 
to specific sources of information to speed up the review process. 
Although the notion of a “rapid review” has emerged, there is 
currently no consistent definition of one (Harker and Kleijnen, 
2012). Where the full systematic review process including devel-
opment and peer review of the protocol would not be feasible in 
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the short timescale required for some questions to be answered, 
a pragmatic review approach would have to be agreed and the 
limitations of such an approach should be clearly stated.
A further challenge likely to arise concerning the use of sys-
tematic reviews in risk assessment and risk management is how 
to decide which of the many questions arising would warrant 
the conduct of a systematic review. An efficient way to prioritize 
questions could be to look at the overall risk assessment and risk 
management process and identify whether there are points in the 
process where the questions arising meet specific priority criteria 
(Aiassa et al., 2015), such as the need for greater precision of a 
parameter estimate and the clarification of uncertainty, or where 
extensive evidence is available that has not hitherto been formally 
critically appraised. An appropriate point in the risk assessment 
and risk management process where this could be considered 
is at the problem formulation step, since this step links the risk 
assessment and risk management process to the protection goal 
and effectively provides a “roadmap” for the rest of the decision-
making process. The conceptual model underpinning the prob-
lem formulation step could provide an appropriate framework for 
determining where systematic reviews could be most valuable.
Apart from their possible application during the regulatory 
approval process, systematic reviews may also help in some cases 
to clarify possible uncertainties about GMO impacts being con-
troversially discussed within the scientific community. The neces-
sity for such a transparent and traceable summary is illustrated by 
a recent article by Hilbeck et al. (2015), discussing the diversity 
of scientific opinions and the problems in achieving a scientific 
consensus in order to conclude about GMO safety.
Future Prospects
For systematic reviews to support GMO risk assessment and/or 
risk management, it is important that stakeholders involved in the 
risk assessment and risk management processes are aware of the 
purpose of systematic reviews as well as the possible limitations 
of non-systematic evidence synthesis approaches. At present, 
it is unclear whether systematic reviews would be widely sup-
ported, for example whether lack of familiarity with the methods, 
limited availability of resources, and a lack of primary research 
data would discourage those involved in risk assessment and risk 
management from conducting systematic reviews. A survey of 
the opinions of stakeholders could help to identify key facilita-
tors of and barriers to the use of systematic reviews in supporting 
GMO risk assessment and risk management. Those who conduct 
systematic reviews will need to be aware of the appropriate 
methods for conducting the review whilst those coordinating 
the risk assessment and risk management will need to be able to 
identify whether a systematic review meets adequate standards of 
conduct. Educational resources or guidance documents to sup-
port these information requirements may need to be provided. 
An advantage of systematic reviews in this respect is that their 
highly standardized methodology is largely independent of the 
topic area, so guidance on how to conduct and appraise system-
atic reviews is already available and can be readily obtained from 
research institutions and organizations in health research, where 
the use of systematic reviews has a long pedigree.
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